Factors affecting 223Ra therapy: clinical experience after 532 cycles from a single institution

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 43, Issue 1, 2016, Pages 8-20

  Etchebehere, Elba C ^a,b   Milton, Denái R ^a   Araujo, John C ^a   Swanston, Nancy M ^a   Macapinlac, Homer A ^a   Rohren, Eric M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

223Ra; Abiraterone; Bone marrow failure; External beam radiation therapy; Prostate cancer; PSA

Indexed keywords

ABIRATERONE; ALKALINE PHOSPHATASE; ENZALUTAMIDE; HEMOGLOBIN; PROSTATE SPECIFIC ANTIGEN; RADIUM CHLORIDE RA 223; RADIUM;

ARTICLE; BONE MARROW DEPRESSION; CANCER CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; EVENT FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; HAZARD RATIO; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; RISK; SCORING SYSTEM; ADULT; AGED; DISEASE FREE SURVIVAL; MIDDLE AGED; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TREATMENT OUTCOME; TUMOR VOLUME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIUM; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84951906696     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-015-3185-4     Document Type: Article

References (18)

1. Hoskin P, Sartor O, O’Sullivan JM, Johannessen DC, Helle SI, Logue J, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol 2014;15:1397–406. doi:10.1016/s1470-2045(14)70474-7.
2. Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213–23. doi:10.1056/NEJMoa1213755.
3. Nilsson S, Franzén L, Parker C, Tyrrell C, Blom R, Tennvall J, et al. Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. Clin Genitourin Cancer 2013;11:20–6. doi:10.1016/j.clgc.2012.07.002.
4. Fizazi K, Massard C, Smith M, Rader M, Brown J, Milecki P, et al. Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer. Eur Urol 2015;68:42–50. doi:10.1016/j.eururo.2014.10.001.
5. Jadvar H, Challa S, Quinn DI, Conti PS. One-year postapproval clinical experience with radium-223 dichloride in patients with metastatic castrate-resistant prostate cancer. Cancer Biother Radiopharm 2015;30:195–9. doi:10.1089/cbr.2014.1802.
6. Kelloff GJ, Coffey DS, Chabner BA, Dicker AP, Guyton KZ, Nisen PD, et al. Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer. Clin Cancer Res 2004;10:3927–33. doi:10.1158/1078-0432.ccr-03-0788.
7. Humm JL, Sartor O, Parker C, Bruland OS, Macklis R. Radium-223 in the treatment of osteoblastic metastases: a critical clinical review. Int J Radiat Oncol Biol Phys 2015;91:898–906. doi:10.1016/j.ijrobp.2014.12.061.
8. Den RB, Doyle LA, Knudsen KE. Practical guide to the use of radium 223 dichloride. Can J Urol 2014;21:70–6.
9. Nilsson S, Larsen RH, Fosså SD, Balteskard L, Borch KW, Westlin JE, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005;11:4451–9. doi:10.1158/1078-0432.ccr-04-2244.
10. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995–2005. doi:10.1056/NEJMoa1014618.
11. Beckett RD, Rodeffer KM, Snodgrass R. Abiraterone for the treatment of metastatic castrate-resistant prostate cancer. Ann Pharmacother 2012;46:1016–24. doi:10.1345/aph.1Q758.
12. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13:983–92. doi:10.1016/s1470-2045(12)70379-0.
13. Hingorani M, Dixit S, Pugazhenthi P, Hawkyard S, Robertson A, Khafagy R. Can palliative radiotherapy influence prostate-specific antigen response in patients with castrate-resistant prostate cancer treated with systemic therapy (chemotherapy or abiraterone)?-a report of three cases. Cancer Biol Med 2015;12:60–3. doi:10.7497/j.issn.2095-3941.2014.0025.
14. Graff JN, Gordon MJ, Beer TM. Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer. Expert Opin Pharmacother 2015;16:749–54. doi:10.1517/14656566.2015.1016911.
15. Tan PS, Haaland B, Montero AJ, Kyriakopoulos CE, Lopes G. Hormonal therapeutics enzalutamide and abiraterone acetate in the treatment of metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel-an indirect comparison. Clin Med Insights Oncol 2014;8:29–36. doi:10.4137/cmo.s13671.
16. Yeku O, Slovin SF. Metabolism and pharmacokinetics of radium-223 in prostate cancer. Expert Opin Drug Metab Toxicol 2015;11:843–9. doi:10.1517/17425255.2015.1021332.
17. Geenen RW, Delaere KP, van Wersch JW. Haematological variables in prostatic carcinoma patients. Acta Urol Belg 1996;64:21–6.
18. Etchebehere E, Araujo JC, Milton D, Fox P, Swanston N, Macapinlac H, et al. Skeletal tumor burden on baseline 18F-fluoride PET/CT to predict bone marrow failure after radium-223. J Clin Oncol 2015;33:S11012.